NCT03237572: Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer

NCT03237572
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Immunotherapy, Therapeutic Antibody, Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Known active central nervous system (CNS) metastases 
https://ClinicalTrials.gov/show/NCT03237572

Comments are closed.

Up ↑